Clover Health Investments, Corp. (CLOV)

Clover Health Investments Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, Clover Health Investments stock has a consensus rating of "Buy" and an average price target of $3.15. The average 1-year stock price forecast is 11.27% lower than the current stock price, while the lowest is $2.75 (-22.54%) and the highest is $3.50 (-1.41%).

Price Target: $3.15 (-11.27%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$2.75	$3.15	$3.20	$3.50
Change	-22.54%	-11.27%	-9.86%	-1.41%

* Price targets were last updated on Mar 20, 2026.

Analyst Ratings

The average analyst rating for Clover Health Investments stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	2	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	1	1	1	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	2	2	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Richard Close Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $3.7 → $3.2	Strong Buy	Maintains	$3.7 → $3.2	-9.86%	Mar 20, 2026
Whit Mayo Leerink Partners	Leerink Partners	Hold Maintains $3 → $2.5	Hold	Maintains	$3 → $2.5	-29.58%	Mar 5, 2026
Richard Close Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $3.7	Strong Buy	Maintains	$3.7	+4.23%	Jan 20, 2026
Richard Close Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $4.1 → $3.7	Strong Buy	Maintains	$4.1 → $3.7	+4.23%	Nov 6, 2025
Richard Close Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $4.5 → $4.1	Strong Buy	Maintains	$4.5 → $4.1	+15.49%	Aug 7, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.97B

Increased by 54.30%

from 1.92B

Revenue Next Year

3.39B

Increased by 14.22%

from 2.97B

EPS This Year

0.01

from -0.17

EPS Next Year

0.01

from 0.01

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.36B	1.20B	1.26B	1.37B	1.92B	2.97B	3.39B
Revenue Growth	97.30%	-11.91%	5.32%	8.52%	40.33%	54.30%	14.22%
EPS	-1.42	-0.71	-0.44	-0.09	-0.17	0.01	0.01
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	261.09	261.09
No. Analysts	-	-	-	-	-	5	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	3.1B	3.6B
Avg	3.0B	3.4B
Low	2.8B	3.2B

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	59.3%	20.0%
Avg	54.3%	14.2%
Low	47.6%	7.0%

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	0.02	0.04
Avg	0.01	0.01
Low	0.01	-0.01

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	-	208.9%
Avg	-	-
Low	-	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.